题名

Correlation between Cytochrome P450 2D6 Genotype and Methadone Concentration-to-dose Ratio

并列篇名

P450 2D6細胞色素基因型與美沙冬血中濃度對劑量比例的相關性

作者

王姿云(Tzu-Yun Wang)；張惠華(Hui Hua Chang)；柯韋名(Wei-Ming Ke)；周辰熹(Chen-Hsi Chou)；李嵐婷(Lan-Ting Lee)；楊延光(Ye-Kuang Yang)；陸汝斌(Ru-Band Lu)；陳柏熹(Po-See Chen)

关键词

藥物動力學 ； 藥物交互作用 ； ＂ABCB1＂ ； pharmacokinetics ； ＂CYP 3A4＂ ； drug interaction

期刊名称

台灣精神醫學

卷期/出版年月

29卷3期（2015 / 09 / 01）

页次

180 - 190+iii

内容语文

英文
中文摘要

目的：美沙冬是一個被用來治療鴉片成癮的合成鴉片類藥品，其療效與副作用和其血中濃度有關。然而濃度對劑量比例有的個別差異，不論是身體或基因因素都會顯著影響接受美沙冬維持治療個案的體重校正後的濃度對劑量比例。本研究目的為調查接受美沙冬維持治療後，基因造成的美沙冬代謝與體重校正後的濃度對劑量比例間的關係。方法：美沙冬血中濃度由HPLC測得。＂CYP2D6*10＂（rs1065852），＂ABCB1C3435T＂（rs1045642）和＂ABCB1G2677T＂（rs2032582）基因的基因型不同由 TaqMan SNP genotyping assays測得。結果：CYP2D6*10基因的多型性和體重校正後的濃度對劑量比例有顯著相關（p＜0.01），而此比例與美沙冬治療個案的副作用有顯著相關（p＜0.01）。結論：比起CYP2D代謝調控不佳者，調控較佳者有較低的體重校正後的濃度對劑量比例，然而是否此調控會影響美沙冬維持治療療效仍需要研究。
英文摘要

Objectives: Methadone is a synthetic opioid used to treat opioid dependence. The therapeutic and side effects are well-noted to be correlated with its blood concentration. But the concentration-to-dose ratio (CDR) is highly varied among individuals. Both physiological and genetic factors that have effects on the weightadjusted CDR in subjects are under methadone maintenance therapy (MMT) in Taiwan. In the current study, we intended to study whether variations of genes associated with methadone metabolism are correlated with the weight-adjusted CDR in patients receiving MTT. Methods: We measured the blood concentration of methadone (CMTD) with high-performance liquid chromatography, and genotyped ＂CYP2D6*10＂ (rs1065852), ＂ABCB1C3435T＂ (rs1045642) and ＂ABCB1G2677T＂ (rs2032582) variations with TaqMan SNP genotyping assays. Results: Results showed that the variation of the ＂CYP2D6*10＂ gene polymorphisms had a signifi-cant effect on the weight-adjusted CDR (p＜0.01), which was signifi cantly associated with the side effects in subjects receiving MTT (p＜0.05). Conclusion: The study results indicated that CYP2D6 extensive metabolizers had lower weightadjusted CDR than that of the poor metabolizers. Whether the variation is also correlated the outcome of the MMT, merits further investigation.
主题分类 醫藥衛生 > 社會醫學
参考文献
  1. Hsu, WY,Liu, JT,Chang, TG,Liao, YC,Chiu, NY(2013).Prevalence of HIV, hepatitis B, hepatitis C in patients participating in the methadone maintenance treatment in central Taiwan.Taiwanse Journal of Psychiatry,27,33-40.
    連結：
  2. Liao, YT,Chiu, CH,Shao, WC(2013).Quality of life among heroin addicts at entry to the methadone maintenance treatment.Taiwanse Journal of Psychiatry,27,52-65.
    連結：
  3. Lin, PY,Liu, ML,Wang, PC,Chang, M(2012).Relationship of monetary subsidy and treatment compliance in heroin addicts following methadone maintenance therapy: the experience of Hsin Chu and Miaoli areas.Taiwanse Journal of Psychiatry,26,19-24.
    連結：
  4. Bell, J,Seres, V,Bowron, P,Lewis, J,Batey, R(1988).The use of serum methadone levels in patients receiving methadone maintenance.Clin Pharmacol Ther,43,623-629.
  5. Bhugra, D(ed.),Tse, S(ed.),Ng, R(ed.),Tokei, N(ed.)(2015).Routledge Handbook of Psychiatry in Asia.London:Routledge.
  6. Brown, R(2004).Heroin dependence.WMJ,103,20-26.
  7. Chen, IM,Huang, CL,Yeh, BJ,Chien, YL(2015).Health service utilization of heroin abusers: a retrospective cohort study.Addict Behav,45,281-286.
  8. Crettol, S,Deglon, JJ,Besson, J(2005).Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9, genotypes, and response to treatment.Clin Pharmacol Ther,78,593-604.
  9. Crettol, S,Deglon, JJ,Besson, J(2006).ABCB1 and cytochrome P450 genotypes and phenotypes: infl uence on methadone plasma levels and response to treatment.Clin Pharmacol Ther,80,668-681.
  10. Davis, AM,Inturrisi, CE(1999).d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia.J Pharmacol Exp Ther,289,1048-1053.
  11. Dilmaghanian, S,Gerber, JG,Filler, SG,Sanchez, A,Gal, J(2004).Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: testosterone and methadone as substrates.Chirality,16,79-85.
  12. Eap, CB,Bourquin, M,Martin, J(2000).Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.Drug Alcohol Depend,61,47-54.
  13. Eap, CB,Broly, F,Mino, A(2001).Cytochrome P450 2D6 genotype and methadone steady-state concentrations.J Clin Psychopharmacol,21,229-234.
  14. Hallinan, R,Ray, J,Byrne, A,Agho, K,Attia, J(2006).Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis.Drug Alcohol Depend,81,129-136.
  15. Hassan, HE,Myers, AL,Coop, A,Eddington, ND(2009).Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.J Pharm Sci,98,4928-4940.
  16. Inturrisi, CE,Verebely, K(1972).Disposition of methadone in man after a single oral dose.Clin Pharmacol Ther,13,923-930.
  17. Kreek, MJ(1981).Metabolic interactions between opiates and alcohol.Ann N Y Acad Sci,362,36-49.
  18. Levran, O,O’Hara, K,Peles, E(2008).ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence.Hum Mol Genet,17,2219-2227.
  19. Loimer, N,Schmid, R(1992).The use of plasma levels to optimize methadone maintenance treatment.Drug Alcohol Depend,30,241-246.
  20. Lugo, RA,Satterfi, eld, KL,Kern, SE(2005).Pharmacokinetics of methadone.J Pain Palliat Care Pharmacother,19,13-24.
  21. Miller, CL,Strathdee, SA,Li, K,Kerr, T,Wood, E(2007).A longitudinal investigation into excess risk for bloodborne infection among young injection drug users (IUDs).Am J Drug Alcohol Abuse,33,527-536.
  22. Nakamura, K,Goto, F,Ray, WA(1985).Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.Clin Pharmacol Ther,38,402-408.
  23. Nutt, D,King, LA,Saulsbury, W,Blakemore, C(2007).Development of a rational scale to assess the harm of drugs of potential misuse.Lancet,369,1047-1053.
  24. Ottomanelli, G(1999).Methadone patients and alcohol abuse.J Subst Abuse Treat,16,113-121.
  25. Pierce, TL,Murray, AG,Hope, W(1992).Determination of methadone and its metabolites by high performance liquid chromatography following solid-phase extraction in rat plasma.J Chromatogr Sci,30,443-447.
  26. Schall, U,Pries, E,Katta, T,Kloppel, A,Gastpar, M(1996).Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone.Addict Biol,1,105-113.
  27. Schwartz, RP,Brooner, RK,Montoya, ID,Currens, M,Hayes, M(1999).A 12-year follow-up of a methadone medical maintenance program.Am J Addict,8,293-299.
  28. Sees, KL,Delucchi, KL,Masson, C(2000).Methadone maintenance vs 180-day psychosocially enriched de- toxifi cation for treatment of opioid dependence: a randomized controlled trial.JAMA,283,1303-1310.
  29. Shen, WW(1997).The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition.Biol Psychiatry,41,814-826.
  30. Shen, WW,Lin, KM(1991).Cytochrome P-450 monooxygenases and interactions of psychotropic drugs.Int J Psychiatry Med,21,47-56.
  31. Shiran, MR,Lennard, MS,Iqbal, MZ(2009).Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.Br J Clin Pharmacol,67,29-37.
  32. Sporer, KA(1999).Acute heroin overdose.Ann Intern Med,130,584-590.
  33. Tennant, FS., Jr.,Rawson, RA,Cohen, A,Tarver, A,Clabough, D(1983).Methadone plasma levels and persistent drug abuse in high dose maintenance patients.Subst Alcohol Actions Misuse,4,369-374.
  34. Vazquez, V,Gury, C,Laqueille, X(2006).Methadone: from pharmacokinetic profi le to clinical pharmacology.Encephale,32,478-486.
  35. Verebely, K,Volavka, J,Mule, S,Resnick, R(1975).Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment.Clin Pharmacol Ther,18,180-190.
print cancel